Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03843294 · ClinicalTrials.gov registry record · Phase 1
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma
A Phase 1 study of Diffuse Large B Cell Lymphoma and Hodgkin Lymphoma, sponsored by Catherine Bollard.
- Active
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT03843294 is a Phase 1 study of Diffuse Large B Cell Lymphoma and Hodgkin Lymphoma that is active but no longer recruiting, run by Catherine Bollard. The registered enrollment target is 18 participants, below the 219-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03843294, a Phase 1 study of Diffuse Large B Cell Lymphoma and Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Catherine Bollard.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I, open-label multi-site trial designed to evaluate the safety of administering rapidly-generated Tumor associated antigen specific T cells (TAA-T) with the Programmed Death1 (PD-1) inhibitor Nivolumab, in relapsed/refractory lymphoma (rel/ref) patients with measurable disease (group A) or as adjunctive therapy following autologous hematopoeitic stem cell transplant(HSCT) for patients at high risk of relapse (group B). The purpose of this study is to find out if the tumor specific T cells given with Nivolumab are safe and to learn what the side effects are and if the combination can help patients with relapsed lymphomas.
Conditions Studied
Interventions
- DRUG Nivolumab
- BIOLOGICAL TAA-T cells
Study Locations (1)
Utah
- Utah University School of Medicine/Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-06-24 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03843294
The ClinicalTrials.gov registry entry for NCT03843294 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (92% lower). The listed sponsor is Catherine Bollard, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT03843294 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT03843294 about?
NCT03843294 is a clinical study titled "Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma". This is a Phase I, open-label multi-site trial designed to evaluate the safety of administering rapidly-generated Tumor associated antigen specific T cells (TAA-T) with the Programmed Death1 (PD-1) inhibitor Nivolumab, in relapsed/refractory lymphoma (rel/ref) patients with measurable disease (group...
What is the current status of trial NCT03843294?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2019-06-24. Estimated completion is 2026-08.
What conditions does trial NCT03843294 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Hodgkin Lymphoma.
What interventions are being tested in trial NCT03843294?
The interventions under investigation include: Nivolumab (DRUG), TAA-T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03843294?
This trial is sponsored by Catherine Bollard, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03843294 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
RECRUITING · Phase 1
-
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.